论文部分内容阅读
目的观察缺血性脑血管病(ICVD)患者应用不同剂量阿司匹林(ASA)抗血小板聚集作用及对血中血栓素B2(TXB2)的影响。方法200例ICVD患者随机分为A1组50例(ASA50mg/d),A2组50例(ASA100mg/d),A3组50例(ASA300mg/d),A4组50例(口服安慰剂),分别于治疗前、治疗2周末、4周末清晨空腹抽血测定花生四烯酸(ACA500ng/dl)诱导的血小板聚集率及血中TXB2。结果与结论阿司匹林抗血小板聚集功能明确,总显效率为27%,总有效率为48%。200例患者治疗前TXB2水平高于正常参考值,经治疗后TXB2在不同ASA剂量组均有所降低且治疗组疗效优于对照组,阿司匹林的作用疗效与剂量的递增无显著相关性,强调个体化用药原则。
Objective To observe the effect of different doses of aspirin (ASA) on platelet aggregation and the level of thromboxane B2 (TXB2) in patients with ischemic cerebrovascular disease (ICVD). Methods A total of 200 ICVD patients were randomly divided into A1 group (ASA 50 mg / d), A2 group (50 cases), ASA group (50 cases), A4 group (50 cases) Before treatment, 2 weeks after treatment, fasting blood samples were taken at the beginning of 4 weeks to determine the platelet aggregation rate and TXB2 level induced by arachidonic acid (ACA500ng / dl). RESULTS AND CONCLUSION Aspirin had a clear anti-platelet aggregation effect with a total effective rate of 27% and a total effective rate of 48%. The level of TXB2 in 200 patients before treatment was higher than the normal reference value. After treatment, TXB2 was decreased in different ASA dose groups and the treatment group was better than the control group. The effect of aspirin did not correlate with dose increase, Principle of medication.